By proceeding, you agree to our Terms of Use and Privacy Policy.
Daniel Oliver is currently working as CEO and Founder at Rejuvenate Bio
Talks About #entrepreneurship #strategy
Preferred Locations #Northamerica
The surge of clinical approvals in CKD and unprecedented use of surrogate endpoints in rare kidney diseases have catalysed a new era of complimentary therapies and precision medicine in drug development for kidney disease.